vimarsana.com
Home
Live Updates
Biohaven Announces Expanded Patient Access to Nurtec® O
Biohaven Announces Expanded Patient Access to Nurtec® O
Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update
/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced two updates regarding Nurtec® ODT (rimegepant), the only FDA-approved...
Related Keywords
United States ,
America ,
Chris Barrett ,
Jennifer Porcelli ,
Mike Beyer ,
Biohaven Neuroinnovation ,
World Health Organization ,
Drug Administration ,
Sam Brown Inc ,
Exchange Commission ,
Government Affairs ,
Biohaven Pharmaceutical Holding Company Ltd ,
Pfizer Inc ,
European Union ,
Academy Of Breastfeeding Medicine ,
Prnewswire Biohaven Pharmaceutical Holding Company Ltd ,
Commercial Lives ,
Lives Covered ,
Lactation Data ,
Patient Information ,
Pharmaceutical Holding Company ,
Broader Commercial Insurance ,
Managed Markets ,
Include Data ,
Specific Populations ,
Elyse Stock ,
Chief Medical ,
Breastfeeding Medicine ,
Medicinal Products ,
Human Use ,
European Medicines Agency ,
Prescribing Information ,
Channel Activators ,
Looking Statements ,
Private Securities Litigation Reform Act ,
Annual Report ,
Biohaven Pharmaceutical Ireland ,
Biohaven Pharmaceutical Holding Company ,
Investor Relations ,
Global Burden ,
Disease Study ,
Lancet Neurol ,